BioMedNewsBreaks

MondayJun 29, 2026 11:44 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform 

Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences validating its proprietary Deciparticle(TM) nanoparticle platform through the development of Sapu003, an investigational intravenous everolimus formulation currently being evaluated in an ongoing Phase 1b clinical trial. The publication details the platform's formulation design, scalable cGMP manufacturing process, product stability and preclinical performance, while demonstrating its potential to enable intravenous delivery of poorly water-soluble therapeutic compounds. The company said the research also supports broader applications for the Deciparticle(TM) platform beyond everolimus, including additional hydrophobic drug candidates. Sapu003 is currently being evaluated in a Phase 1b dose-escalation study in patients with advanced mTOR-sensitive solid tumors…

Continue Reading

MondayJun 29, 2026 9:10 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches AI Agent Platform for Patient Scheduling and Care Coordination

HealthLynked (OTCQB: HLYK) announced the launch of its next-generation AI Agent Platform, a conversational voice AI solution designed to automate patient scheduling, care coordination and healthcare communications for both patients and providers. The platform supports inbound and outbound voice interactions, enabling AI agents to schedule appointments, navigate physician office phone systems, collect patient and insurance information, perform intake functions, confirm appointments and provide 24/7 answering services for healthcare practices. The company said the platform is designed to help physician practices, accountable care organizations, health systems and insurers improve patient access while reducing administrative burdens and staffing requirements. HealthLynked plans a phased…

Continue Reading

FridayJun 26, 2026 2:22 pm

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Analytics Beyond Traditional Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection. The company was featured in a recent article that discussed its efforts to broaden the scope of its platform with the development of a fatigue prediction model designed for high-risk workplace environments. “The fatigue detection capability is expected to become an additional feature within MindBio’s planned Edge AI Intoxication Detection Kiosks, which are being designed to identify signs of alcohol, drug impairment and fatigue from short voice…

Continue Reading

FridayJun 26, 2026 11:47 am

BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) MyndRenew(TM) Earns TruShield Certification

BioAdaptives (OTC: BDPT) announced that MyndRenew(TM), the nighttime component of its MyndSystem(TM) cognitive health platform, has received TruShield Certified status, confirming compliance with anti-doping standards established by the World Anti-Doping Agency and the UFC. Combined with the previously certified MyndMed(TM) daytime formula, the company said MyndSystem(TM) is now a fully WADA-compliant 24/7 cognitive performance and recovery system for professional athletes. The company said the certification strengthens its position in the sports nutrition market by supporting potential adoption among professional athletes while also targeting executives and active seniors. BioAdaptives said the milestone could enhance commercialization opportunities, strategic partnerships and broader market adoption as it expands the MyndSystem(TM) platform. To view the full press release, visit https://ibn.fm/JNHRs About BioAdaptives, Inc. BioAdaptives,…

Continue Reading

FridayJun 26, 2026 11:40 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in NetworkNewsAudio Editorial on DNA Repair Therapies 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced its inclusion in a NetworkNewsAudio Audio Press Release highlighting the company's approach to next-generation DNA repair therapies for cancer. The audio feature, titled "Next-Generation DNA Repair Therapies Open New Frontiers in Oncology," accompanies a previously published editorial examining the emerging opportunity for PNKP inhibitors within the expanding DNA Damage Response ("DDR") oncology market. The feature highlights Onco-Innovations' exclusive global rights to a portfolio of PNKP inhibitor technology, including core inhibitor molecules, nanoparticle drug delivery technology and synthetic lethality applications designed to target cancer cells. The company said this combination of molecular, delivery…

Continue Reading

FridayJun 26, 2026 10:05 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in NetworkNewsAudio Editorial on Multiple Sclerosis

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced its inclusion in a NetworkNewsAudio Audio Press Release highlighting the company's novel approach to treating multiple sclerosis ("MS"). The audio feature, titled "Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis," accompanies a previously published editorial discussing the growing need for therapies that go beyond symptom management in a global MS therapeutics market projected to reach $38.62 billion by 2030. The feature highlights Quantum BioPharma's lead candidate, Lucid-MS, a patented, first-in-class drug candidate designed…

Continue Reading

ThursdayJun 25, 2026 11:45 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that it is featured in a BioMedWire editorial examining the need for new approaches to treating multiple sclerosis ("MS"), a progressive neurological disease affecting more than 2.9 million people worldwide. The editorial, titled "The Quest to Repair What Multiple Sclerosis Takes Away," highlights the limitations of current therapies, which can slow disease progression but cannot stop it completely. The editorial discusses Quantum BioPharma's development of Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company said the potential therapy is preparing to advance…

Continue Reading

ThursdayJun 25, 2026 11:11 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reorganizes to Accelerate Global Commercialization Strategy 

HeartBeam (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role. The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems,…

Continue Reading

ThursdayJun 25, 2026 9:20 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on Emerging DNA Repair Inhibitors

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced it is featured in a BioMedWire editorial examining the growing market opportunity for next-generation DNA Damage Response ("DDR") inhibitors. The editorial, titled "Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market," highlights the continued expansion of DDR-targeted therapies beyond PARP inhibitors as the global oncology, diagnostics and precision medicine markets continue to grow. The editorial highlights Onco-Innovations' lead candidate, ONC010™, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple repair pathways. The…

Continue Reading

WednesdayJun 24, 2026 1:53 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Eyes Opportunity Through AI and Pharmaceutical Automation

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s efforts to move beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. The publication reads, “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments… At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise,…

Continue Reading